目的 探討復(fù)方雙花片聯(lián)合布地奈德治療慢性咽炎的臨床效果。方法 選取南陽市中心醫(yī)院2016年2月-2017年2月收治的慢性咽炎患者101例，隨機分成對照組（50例）和治療組（51例）。對照組患者鼻腔霧化吸入布地奈德氣霧劑，0.5 mg/次，3次/d。治療組在對照組的基礎(chǔ)上口服復(fù)方雙花片，4片/次，3次/d。所有患者均經(jīng)過規(guī)律治療1周。評價兩組患者臨床療效，同時比較治療前后兩組患者臨床癥狀改善時間、血清炎性指標(biāo)和不良反應(yīng)差異。結(jié)果 治療后，對照組和治療組臨床總有效率分別為82.00%、96.08%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，治療組癥狀改善時間明顯短于對照組患者，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者腫瘤壞死因子-α（TNF-α）、C反應(yīng)蛋白（CRP）和IL-6水平均顯著性降低，同組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者炎性指標(biāo)水平明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療期間，對照組患者不良反應(yīng)發(fā)生率為22.00%，明顯高于治療組的5.88%，兩組不良反應(yīng)比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 復(fù)方雙花片聯(lián)合布地奈德治療慢性咽炎療效顯著，安全性高，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical effect of Compound Shuanghua Tablets combined with budesonide in treatment of chronic pharyngitis. Methods Patients (101 cases) with chronic pharyngitis in Nanyang City Center Hospital from February 2016 to February 2017 were randomly divided into control (50 cases) and treatment (51 cases) groups. Patients in the control group were nasal cavity aerosol inhalation administered with Budesonide Aerosol, 0.5 mg/time, three times daily. Patients in the treatment group were po administered with Compound Shuanghua Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 1 week. After treatment, the clinical efficacy was evaluated, and the difference of the clinical symptom improvement time, serum inflammatory markers, and adverse reactions in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control and treatment groups were 82.00% and 96.08%, respectively, and there were differences between two groups (P<0.05). After treatment, the clinical symptom improvement time in the treatment group was obviously shorter than those in the control group, with significant difference between two groups (P<0.05). After treatment, the TNF-α, CRP, and IL-6 levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And these serum inflammatory markers in the treatment group were obviously lower than those in the control group, with significant difference between two groups (P<0.05). During the treatment, the incidence of adverse reactions in the control group was 22.00%, which were significantly higher than 5.88% in the treatment group, with significant difference between two groups (P<0.05). Conclusion Compound Shuanghua Tablets combined with budesonide has significant effect in treatment of chronic pharyngitis with high safety, which has a certain clinical application value.